NASDAQ:KRON

Kronos Bio Competitors

$25.41
-1.87 (-6.85 %)
(As of 04/12/2021 05:20 PM ET)
Add
Compare
Today's Range
$25.30
Now: $25.41
$27.21
50-Day Range
$27.21
MA: $28.63
$29.51
52-Week Range
$25.30
Now: $25.41
$39.60
Volume459,980 shs
Average Volume182,063 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Kronos Bio (NASDAQ:KRON) Vs. SRPT, ALLK, BPMC, PRGO, SDGR, and GLPG

Should you be buying KRON stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Kronos Bio, including Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), and Galapagos (GLPG).

Sarepta Therapeutics (NASDAQ:SRPT) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Profitability

This table compares Sarepta Therapeutics and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Kronos BioN/AN/AN/A

Valuation & Earnings

This table compares Sarepta Therapeutics and Kronos Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million14.47$-715,080,000.00($9.71)-7.15
Kronos BioN/AN/AN/AN/AN/A

Kronos Bio has lower revenue, but higher earnings than Sarepta Therapeutics.

Insider and Institutional Ownership

89.7% of Sarepta Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sarepta Therapeutics and Kronos Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191202.50
Kronos Bio00403.00

Sarepta Therapeutics presently has a consensus target price of $150.4762, suggesting a potential upside of 116.89%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Sarepta Therapeutics' higher probable upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Kronos Bio.

Summary

Sarepta Therapeutics beats Kronos Bio on 5 of the 9 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Allakos and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
Kronos BioN/AN/AN/A

Valuation and Earnings

This table compares Allakos and Kronos Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-55.24
Kronos BioN/AN/AN/AN/AN/A

Insider and Institutional Ownership

65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Allakos and Kronos Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
Kronos Bio00403.00

Allakos presently has a consensus target price of $181.50, suggesting a potential upside of 73.83%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Allakos' higher probable upside, equities research analysts clearly believe Allakos is more favorable than Kronos Bio.

Summary

Allakos beats Kronos Bio on 3 of the 5 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Blueprint Medicines and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Kronos BioN/AN/AN/A

Valuation and Earnings

This table compares Blueprint Medicines and Kronos Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million80.70$-347,690,000.00($7.27)-12.74
Kronos BioN/AN/AN/AN/AN/A

Kronos Bio has lower revenue, but higher earnings than Blueprint Medicines.

Analyst Ratings

This is a summary of recent recommendations for Blueprint Medicines and Kronos Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
Kronos Bio00403.00

Blueprint Medicines presently has a consensus target price of $111.00, suggesting a potential upside of 19.86%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Kronos Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kronos Bio is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Kronos Bio on 6 of the 8 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Perrigo and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Kronos BioN/AN/AN/A

Valuation and Earnings

This table compares Perrigo and Kronos Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.12$146.10 million$4.0310.05
Kronos BioN/AN/AN/AN/AN/A

Perrigo has higher revenue and earnings than Kronos Bio.

Insider and Institutional Ownership

82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Perrigo and Kronos Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Kronos Bio00403.00

Perrigo presently has a consensus target price of $52.00, suggesting a potential upside of 28.33%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Kronos Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kronos Bio is more favorable than Perrigo.

Summary

Perrigo beats Kronos Bio on 5 of the 9 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Schrödinger and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Kronos BioN/AN/AN/A

Institutional & Insider Ownership

41.3% of Schrödinger shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Schrödinger and Kronos Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million60.47$-24,570,000.00N/AN/A
Kronos BioN/AN/AN/AN/AN/A

Kronos Bio has lower revenue, but higher earnings than Schrödinger.

Analyst Ratings

This is a summary of current ratings for Schrödinger and Kronos Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Kronos Bio00403.00

Schrödinger currently has a consensus price target of $85.50, indicating a potential upside of 15.73%. Kronos Bio has a consensus price target of $43.6667, indicating a potential upside of 71.85%. Given Kronos Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kronos Bio is more favorable than Schrödinger.

Summary

Kronos Bio beats Schrödinger on 6 of the 8 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Galapagos and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos-70.67%-11.78%-5.58%
Kronos BioN/AN/AN/A

Institutional & Insider Ownership

11.2% of Galapagos shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Galapagos and Kronos Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion5.05$167.83 million$5.4614.17
Kronos BioN/AN/AN/AN/AN/A

Galapagos has higher revenue and earnings than Kronos Bio.

Analyst Ratings

This is a summary of current ratings for Galapagos and Kronos Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos211402.12
Kronos Bio00403.00

Galapagos currently has a consensus price target of $143.7273, indicating a potential upside of 85.72%. Kronos Bio has a consensus price target of $43.6667, indicating a potential upside of 71.85%. Given Galapagos' higher probable upside, equities research analysts clearly believe Galapagos is more favorable than Kronos Bio.


Kronos Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$69.38-1.7%$5.60 billion$380.83 million-8.87
Allakos logo
ALLK
Allakos
1.7$104.41-0.6%$5.58 billionN/A-38.11
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.61-1.7%$5.46 billion$66.51 million17.09
Perrigo logo
PRGO
Perrigo
2.5$40.52-0.0%$5.41 billion$4.84 billion-675.22
Schrödinger logo
SDGR
Schrödinger
1.5$73.88-0.0%$5.17 billion$85.54 million0.00Insider Selling
Galapagos logo
GLPG
Galapagos
1.3$77.39-0.5%$5.10 billion$1.00 billion-11.73Analyst Report
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$55.31-2.2%$4.68 billionN/A0.00
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.68-2.6%$4.47 billion$6.87 million-7.22Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.77-1.9%$4.31 billionN/A-5.77Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.30-0.2%$4.26 billion$204.89 million-36.63
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86-2.0%$4.12 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.76-2.4%$4.00 billion$806.43 million-9.17Unusual Options Activity
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$74.94-5.4%$3.87 billionN/A-21.35High Trading Volume
News Coverage
LEGN
Legend Biotech
1.2$27.81-2.3%$3.76 billion$64.39 million0.00
I-Mab logo
IMAB
I-Mab
1.4$47.86-7.9%$3.72 billion$4.31 million-1.66
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.24-1.0%$3.64 billion$117.91 million-10.60
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31-6.7%$3.44 billion$36.13 million-69.12Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68-0.3%$3.40 billion$114.62 million-7.53Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.13-1.0%$3.35 billion$306.98 million-6.74
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.59-0.1%$3.34 billionN/A-5.61
Insmed logo
INSM
Insmed
1.2$30.82-2.9%$3.27 billion$136.47 million-11.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.43-0.2%$3.26 billion$339.08 million-11.88
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.87-3.0%$3.20 billion$26.52 million-7.57
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.62-3.8%$3.16 billionN/A-56.03
Arvinas logo
ARVN
Arvinas
1.5$60.45-5.0%$3.10 billion$42.98 million-23.61
Alkermes logo
ALKS
Alkermes
1.4$18.78-1.3%$3.03 billion$1.17 billion-40.83Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.95-0.4%$2.99 billion$421.03 million23.93Analyst Report
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.17-0.9%$2.94 billion$80.43 million105.58
Organogenesis logo
ORGO
Organogenesis
1.0$22.98-0.6%$2.92 billion$260.98 million-383.00Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.80 billion$901.90 million-22.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.79 billion$644.77 million-10.36
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.66 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.56 billion$60,000.00-9.85News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.56 billionN/A0.00
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.55 billion$120.28 million-146.36
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.53 billion$2.11 million-8.65
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.52 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.43 billionN/A-22.51
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.43 billion$182.24 million-8.08
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.38 billion$33.94 million-89.03Insider Selling
Xencor logo
XNCR
Xencor
1.2$39.59-2.2%$2.35 billion$156.70 million-28.28News Coverage
Amarin logo
AMRN
Amarin
1.6$5.84-1.5%$2.33 billion$429.76 million-116.78
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49-2.7%$2.22 billion$15 million-15.96
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30-1.2%$2.18 billion$963.01 million13.76
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.10-10.3%$2.10 billionN/A-26.43Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.91-0.8%$2.01 billion$410,000.00-6.07
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.18-0.3%$1.99 billion$23.90 million-16.26Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.89-2.1%$1.98 billionN/A-19.29
MORF
Morphic
1.3$57.73-2.8%$1.93 billion$16.98 million-37.01Insider Selling
News Coverage
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.